Houel R, Le Besnerais P, Soustelle C, Kirsch M, Hillion M L, Loisance D
Service de Chirurgie Thoracique et Cardiovasculaire, CNRS UPRES A 7054, Association Claude Bernard, Hopital Henri Mondor, Creteil, France.
J Heart Valve Dis. 1999 Jul;8(4):368-74; discussion 374-5.
The aim of the study was to compare the durability and risk of reoperation in patients undergoing isolated aortic valve replacement with either a porcine standard Carpentier Edwards or a Mitroflow pericardial valve.
Follow up evaluation was performed in 118 patients receiving a Mitroflow valve (M) and 94 patients receiving a standard Carpentier Edwards porcine valve (CE) between 1980 and 1987. The two groups were identical in terms of clinical characteristics; only prosthesis size differed, with small-sized valves used more frequently among the Mitroflow group.
The risk of structural valve deterioration (SVD) was 2.3% per patient-year (pt-yr) in CE valves, and 5.4 per pt-yr in M valves. Freedom from SVD was 100%, 87 +/- 4% and 63 +/- 8% at 5, 10 and 15 years for CE valves, and 96 +/- 2%, 56 +/- 7% and 5 +/- 4% for M valves. Freedom of reoperation was 98 +/- 1%, 83 +/- 5% and 76 +/- 7% at 5, 10 and 15 years respectively for CE valves, and 94 +/- 2%, 55 +/- 7% and 11 +/- 9% for M valves. Despite the high number of valve-related reoperations, survival at 5, 10 and 15 years was not affected in M valve patients. Multivariate analysis (Cox model) showed that age and valve type were the two main risk factors for SVD and reoperation, though the latter factor had no impact on survival.
In younger patients (aged < 75 years), the CE valves offer superior results to the M counterpart in valve replacement. However, in patients aged > 75 years, pericardial and porcine bioprostheses demonstrate equivalent durability, despite post-implantation tissue changes in the former material.
本研究旨在比较接受猪源标准卡朋蒂埃-爱德华兹瓣膜或米特罗流心包瓣膜单纯主动脉瓣置换术患者的瓣膜耐久性及再次手术风险。
对1980年至1987年间接受米特罗流瓣膜(M组)的118例患者和接受标准卡朋蒂埃-爱德华兹猪瓣膜(CE组)的94例患者进行随访评估。两组患者的临床特征相同;仅假体尺寸不同,米特罗流组更频繁使用小尺寸瓣膜。
CE瓣膜患者每年的结构瓣膜退变(SVD)风险为2.3%,M瓣膜患者每年为5.4%。CE瓣膜在5年、10年和15年时无SVD的比例分别为100%、87±4%和63±8%,M瓣膜分别为96±2%、56±7%和5±4%。CE瓣膜在5年、10年和15年时再次手术率分别为98±1%、83±5%和76±7%,M瓣膜分别为94±2%、55±7%和11±9%。尽管与瓣膜相关的再次手术数量较多,但M瓣膜患者在5年、10年和15年时的生存率未受影响。多因素分析(Cox模型)显示,年龄和瓣膜类型是SVD和再次手术的两个主要风险因素,尽管后一因素对生存率无影响。
在年轻患者(年龄<75岁)中,CE瓣膜在瓣膜置换方面的效果优于M瓣膜。然而,在年龄>75岁的患者中,尽管心包生物假体植入后会发生组织变化,但心包生物假体和猪生物假体的耐久性相当。